Duligotuzumab

From Food & Medicine Encyclopedia

(Redirected from Duligotumab)

Duligotuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Merck KGaA and ImClone Systems.

Mechanism of Action[edit]

Duligotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). By binding to these receptors, duligotuzumab inhibits the growth and proliferation of cancer cells that overexpress these receptors.

Clinical Trials[edit]

Duligotuzumab has been studied in clinical trials for the treatment of various types of cancer, including head and neck cancer, colorectal cancer, and non-small cell lung cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.

Side Effects[edit]

Like all drugs, duligotuzumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, diarrhea, and skin rash. In some cases, these side effects can be severe and may require medical attention.

See Also[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Duligotuzumab&oldid=6528089"